Replies to post #21701 on RespireRx Pharmaceuticals Inc (fka RSPI)

[scstocks]

Hello neuroinv,

Thanks for taking the time to post.

Yikes, your comment that "There is an undercurrent of fear at this meeting that is not like anything I have seen in several years.," was unfortunately, not that unexpected.

I just couldn't see big pharma, even with their billions, replacing the normal, now mostly choked off, flow of funds for most stocks out there with funding needs.

I can just picture the "action rooms" of the big pharma houses, with their dartboards of interesting companies to be had on the cheap. Hopefully cor will be one of them, as the alternative is not good, for them, or those they might one day help. They do have a great book of patents, as well.

We will be looking forward to your posts in the days ahead.

Take Care.

[iggs]

Well Neuro...thanks for the vote of confidence. I agree it is a tough environment. I am curious, what was Varney's demeanor? The company must feel boxed in at this point....

Iggs

[haysaw]

Thanks for the insight and stories, Neuro.

You make a case for heightened leverage for BP, in light of the bargains and desperation out there in biotechland. My question is: How much does this matter if/when several interested (BP) parties enter the fray for a novel compound w/out competition (assuming Cor can create that buzz)? Does Cortex have what it takes to stay strong and patient in a room of powerful BP negotiators looking to author the terms of a deal? I hope they can, although I have my doubts.

Also, do they have the ability to seek out an alternative funding plan (absent a good BP partnership or good R&R/JMP financing)? My concern is, that since they have been very conventional/uncreative in this arena in the last several years, we will get more of the same disappointment.

Finally, was Ceph at the Wyndhover Conf?

Thanks in advance.

[scstocks]

<<<One statistic is that there are over 120 biotechs with less than six months of cash.>>>

Hello neuroinv,

Kind of an obvious question, but are those 120 Companies listed anywhere online, or where those just some generic numbers being tossed out for consideration?

I would be interested to see just which companies are in need of cash within the next 6 months, listed all in one place.

I figure, it's a long shot, but worth asking, if you get time to respond.

Take Care.

PS, Cor price held up well this morning with no change as of 10:35....

[K-G]

Neuro,

Thank you for the informative post. I think there are a couple of additional things that you should that you should also consider. First, Cortex is amoung the very few small biotechs whose valuation has increased over the past year. Their 'crash' occurred last year, so while the company's share price has decreased over the past few months, the value in a partnership is significantly greater because of the recent clinical successes than just a few months ago.

Second, it is not in the interest of BP to force painful terms on the partnering company. It serves no purpose to sign a deal on terms whereby the small company does not gain sufficient resourses to live up to their side of the partnership. The same cannot be said about an acquisition, and the BP comment you mentioned about accepting their lowered valuation applies to these cases.

Finally, very few biotech products pose the kind of threat to existing product lines that Cortex's RD application does to opioid formulations. There are at least a couple of companies (I think you mentioned J&J and Cephalon.) that derive significant revenue from the sale of opioid pain medications. These revenue streams could be destroyed by the introduction of an RD risk-free opioid product line.

So, all-in-all, while the environment is horrible compared to a couple of years ago, I think Cortex should still be able to come away with a good deal.

Thanks,
Karl